M. Ramgopal

发表

Origin of the dengue virus outbreak in Martin County, Florida, USA 2013.

Frank D. Teets, S. Michael, M. Ramgopal, 2014, Virology reports.

The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation

Jack T Stapleton, Stuart Haber, David Heckerman, 2010, Science.

Vesatolimod, a toll-like receptor 7 agonist, induces immune activation in virally suppressed adults with HIV-1.

T. Wrin, J. Mellors, R. Begley, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens

R. Haubrich, M. Das, D. Asmuth, 2020, PloS one.

A Phase IIa Study Evaluating Safety, Pharmacokinetics, and Antiviral Activity of GSK2838232, a Novel, Second-generation Maturation Inhibitor, in Participants With Human Immunodeficiency Virus Type 1 Infection.

M. Ramgopal, E. Dejesus, E. Dumont, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

A Rare Case of Mycobacterium abscessus Mitral Valve Endocarditis Treated With Antimycobacterial Therapy

Jaymin Patel, M. Ramgopal, P. Chalasani, 2015 .

Spinal osteomyelitis due to Mycobacterium fortuitum in a former intravenous drug user

M. Ramgopal, Ahkeel Allen, Katie Longardner, 2013, BMJ Case Reports.

Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.

D. Dieterich, S. Henn, M. Ramgopal, 2015, The New England journal of medicine.

Cobicistat-Boosted Protease Inhibitors in HIV-Infected Patients with Mild to Moderate Renal Impairment

F. Post, M. Ramgopal, M. Fisher, 2014, HIV clinical trials.

Randomized study evaluating the efficacy and safety of switching from an an abacavir/lamivudine-based regimen to an elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide single-tablet regimen.

R. Haubrich, H. Stellbrink, M. Das, 2019, AIDS.

HIV Drug Therapy in the Americas 16–18 April 2015, Mexico City, Mexico

M. Lederman, D. Podzamczer, D. Kuritzkes, 2015, Journal of the International AIDS Society.

Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study

M. Murray, M. Ramgopal, J. Mrus, 2019, HIV research & clinical practice.

Proactive strategies to optimize engagement of Black, Hispanic/Latinx, transgender, and nonbinary individuals in a trial of a novel agent for HIV pre-exposure prophylaxis (PrEP)

J. Baeten, K. Mounzer, M. Das, 2022, PloS one.

12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens

M. Ramgopal, A. Luetkemeyer, R. Bhore, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Viral hepatitis: progress and problems.

M. Ramgopal, T. Kiernan, 1979, The Medical clinics of North America.

Ibrutinib for Hospitalized Adults With Severe Coronavirus Disease 2019 Infection: Results of the Randomized, Double-Blind, Placebo-Controlled iNSPIRE Study

S. Treon, M. Ramgopal, S. Coutre, 2022, Open forum infectious diseases.

Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment.

M. Ramgopal, E. Dejesus, S. Segal-Maurer, 2018, AIDS research and human retroviruses.

High-resolution proteomics identifies potential new markers of Zika and dengue infections

Hyungwon Choi, C. Vogel, E. Ghedin, 2019, bioRxiv.

Single-cell TCR sequencing reveals phenotypically diverse clonally expanded cells harboring inducible HIV proviruses during ART

J. Routy, M. Ramgopal, R. Fromentin, 2020, Nature Communications.

Risk Factors for Suboptimal Adherence Identified by Patient-Reported Outcomes Assessments in Routine HIV Care at 2 North American Clinics

W. Lober, M. Ramgopal, H. Crane, 2022, Patient preference and adherence.

Utility and Impact of the Implementation of Same-Day, Self-administered Electronic Patient-Reported Outcomes Assessments in Routine HIV Care in two North American Clinics

W. Lober, M. Ramgopal, H. Crane, 2022, AIDS and Behavior.

PPA_A_378335 2461..2472

M. Ramgopal, H. Crane, J. Bacon, 2022 .

Interleukin-7 promotes HIV persistence during antiretroviral therapy.

M. Lederman, J. Routy, R. Sékaly, 2013, Blood.

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

R. Haubrich, M. Kozal, K. Tashima, 2014, The Journal of infectious diseases.

Paradoxical immune reconstitution inflammatory syndrome presenting as acute respiratory distress syndrome in a non‐HIV immunosuppressed sarcoidosis patient

M. Ramgopal, Vishal Dahya, J. Glickman, 2014, International journal of rheumatic diseases.

Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study

K. Lichtenstein, F. Post, Samir K. Gupta, 2016, Journal of acquired immune deficiency syndromes.

Tuberculosis Infection Status Post Partial Knee Arthroplasty: A Novel Treatment Approach

M. Ramgopal, Sheldon T. Brown, Vishal Dahya, 2016 .

1002. A Daily Single Tablet Regimen (STR) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Virologically-Suppressed Adults Living with HIV and End Stage Renal Disease on Chronic Hemodialysis

D. Asmuth, J. Slim, J. Eron, 2020, Open Forum Infectious Diseases.

Mycobacterium bovis Cervical Discitis as a Complication of Intravesicular Bacillus Calmette-Guérin Irrigation Treatment

M. Ramgopal, Vishal Dahya, Tove Boss, 2015 .

Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV

A. Zolopa, M. Ramgopal, Tulika Singh, 2021, AIDS.

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

B. Gazzard, K. Tashima, M. Shields, 2019, The Lancet.

1060. Pritelivir in Immunocompromised Patients with Mucocutaneous Acyclovir-Resistant Herpes Simplex Virus-Infections – First Case Series

J. Schiffer, M. Ison, A. Wald, 2021, Open Forum Infectious Diseases.

Pharmacokinetics of Total and Unbound Etravirine in HIV-1–Infected Pregnant Women

M. Ramgopal, C. Zorrilla, H. Crauwels, 2016, Journal of acquired immune deficiency syndromes.

P029: Safety of tenofovir alafenamide in renal impairment

K. Lichtenstein, F. Post, Samir K. Gupta, 2015 .

Dolutegravir versus Placebo in Subjects Harbouring HIV-1 with Integrase Inhibitor Resistance Associated Substitutions: 48-Week Results from VIKING-4, a Randomized Study

M. Ramgopal, B. Wynne, B. Akil, 2015, Antiviral therapy.

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

P. Cahn, M. Ramgopal, A. Pozniak, 2013, The Lancet.

Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial

Shan-Chwen Chang, M. Ramgopal, P. Delobel, 2023, Infection.

New Proteomic Signatures to Distinguish Between Zika and Dengue Infections

Hyungwon Choi, C. Vogel, E. Ghedin, 2021, Molecular & cellular proteomics : MCP.

Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1

M. Kozal, J. Aberg, A. Streinu-Cercel, 2021, AIDS.

Cross-Clade Ultrasensitive PCR-Based Assays To Measure HIV Persistence in Large-Cohort Studies

Jintanat Ananworanich, Nelson Michael, Jerome H. Kim, 2014, Journal of Virology.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

Genitourinary tuberculosis after renal transplantation: report of 3 cases and review.

C. Mies, G. Ciancio, G. Burke, 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Switching from ritonavir to cobicistat in HIV patients with renal impairment who are virologically suppressed on a protease inhibitor

M. Ramgopal, G. Moyle, M. Fisher, 2014, Journal of the International AIDS Society.

Dengue Outbreak in Martin County, Florida in 2013

T. Ross, G. Kirchenbaum, M. Ramgopal, 2015 .

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Rapid-Initiation Model of Care for Human Immunodeficiency Virus Type 1 Infection: Primary Analysis of the DIAMOND Study

R. Bolan, M. Ramgopal, R. Nettles, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Catastrophic antiphospholipid syndrome (CAPS) induced by influenza A virus subtype H1N1

M. Ramgopal, Diana L. Marchese, Marjorie D. Robinson, 2013, BMJ Case Reports.

Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study

M. Saag, M. Ramgopal, D. Brainard, 2021, Journal of acquired immune deficiency syndromes.

Impact of age and pre-existing influenza immune responses in humans receiving split inactivated influenza vaccine on the induction of the breadth of antibodies to influenza A strains

James D. Allen, T. Vogel, S. Delagrave, 2017, PloS one.

Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.

Y. Yazdanpanah, A. Antinori, A. Clarke, 2019, The lancet. HIV.

Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.

A. LaMarca, H. Stellbrink, F. Post, 2017, The lancet. HIV.

The Intelence aNd pRezista Once A Day Study (INROADS): a multicentre, single‐arm, open‐label study of etravirine and darunavir/ritonavir as dual therapy in HIV‐1‐infected early treatment‐experienced subjects

M. Ramgopal, C. Brinson, R. Ryan, 2015, HIV medicine.

Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial.

J. Baeten, Samir K. Gupta, M. Ramgopal, 2023, The lancet. HIV.

Clostridium ramosum Osteomyelitis in an Immunocompetent Patient After Traumatic Injury

M. Ramgopal, Vishal Dahya, Marjorie D. Robinson, 2015 .

LB-7. Weight Change in Suppressed People with HIV (PWH) Switched from Either Tenofovir Disoproxil Fumarate (TDF) or Abacavir (ABC) to Tenofovir Alafenamide (TAF)

P. Sax, K. Mounzer, T. Brown, 2020, Open Forum Infectious Diseases.

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.

A. LaMarca, D. Podzamczer, A. Lazzarin, 2017, The lancet. HIV.

The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy

T. Wrin, J. Mellors, R. Begley, 2021, Science Translational Medicine.

Impact of age and pre-existing immunity on the induction of human antibody responses against influenza B viruses

T. Ross, H. Kleanthous, M. Ramgopal, 2019, Human vaccines & immunotherapeutics.

Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority t

S. Oka, S. Walmsley, G. di Perri, 2023, The lancet. HIV.

The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation

R. C. Rose, Todd M. Allen, David S. Rubin, 2010, Science.

Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial.

M. Ramgopal, A. Mills, O. Osiyemi, 2024, The lancet. HIV.